UK Continues to Face ADHD Medication Shortages
What happened
Patients and pharmacists in the UK report ongoing difficulties sourcing necessary ADHD medications. The persistent shortages underscore the importance of non-pharmacological interventions like coaching and skill-building, particularly when medication access is unpredictable.
Why it matters
- The national ADHD medication shortage in the UK began in September 2023, initially expected to resolve by December 2023, but has persisted due to a combination of manufacturing issues and a surge in global demand. - A survey revealed the significant impact on patients, with only 8% receiving their medication without interruption. Many patients have been forced to ration their medication, and 44% have expressed concern about potentially losing their jobs due to the shortages. - The supply disruption affects several key medications, including methylphenidate (e.g., Concerta XL, Equasym XL), lisdexamfetamine (Elvanse), guanfacine (Intuniv), and atomoxetine. The availability of specific brands and dosages varies and can change with little notice. - In response to the crisis, the Department of Health and Social Care issued a National Patient Safety Alert and has advised clinicians to temporarily halt prescribing these medications to newly diagnosed patients. - The supply chain remains fragile, with some medications becoming available intermittently. This unpredictability makes it difficult for patients to know if their prescriptions can be filled, leading them to contact multiple pharmacies. - The shortages are not unique to the UK; the United States is also experiencing similar issues with ADHD medication supply. - Healthcare providers have been advised to consider switching patients to alternative medications or different release formulations that may have better availability, though this requires careful clinical supervision. - Due to the shortages, it may not be feasible to provide separate medication supplies for a child's school and home, requiring coordination between parents and schools to share a single supply.
Key numbers
- - The national ADHD medication shortage in the UK began in September 2023, initially expected to resolve by December 2023, but has persisted due to a combination of manufacturing issues and a surge in global demand.
- A survey revealed the significant impact on patients, with only 8% receiving their medication without interruption.
- Many patients have been forced to ration their medication, and 44% have expressed concern about potentially losing their jobs due to the shortages.
What happens next
- The national ADHD medication shortage in the UK began in September 2023, initially expected to resolve by December 2023, but has persisted due to a combination of manufacturing issues and a surge in global demand.
- Healthcare providers have been advised to consider switching patients to alternative medications or different release formulations that may have better availability, though this requires careful clinical supervision.
- Due to the shortages, it may not be feasible to provide separate medication supplies for a child's school and home, requiring coordination between parents and schools to share a single supply.
Quick answers
What happened in UK Continues to Face ADHD Medication Shortages?
Patients and pharmacists in the UK report ongoing difficulties sourcing necessary ADHD medications. The persistent shortages underscore the importance of non-pharmacological interventions like coaching and skill-building, particularly when medication access is unpredictable.
Why does UK Continues to Face ADHD Medication Shortages matter?
The national ADHD medication shortage in the UK began in September 2023, initially expected to resolve by December 2023, but has persisted due to a combination of manufacturing issues and a surge in global demand. A survey revealed the significant impact on patients, with only 8% receiving their medication without interruption. Many patients have been forced to ration their medication, and 44% have expressed concern about potentially losing their jobs due to the shortages. The supply disruption affects several key medications, including methylphenidate (e.g., Concerta XL, Equasym XL), lisdexamfetamine (Elvanse), guanfacine (Intuniv), and atomoxetine. The availability of specific brands and dosages varies and can change with little notice. In response to the crisis, the Department of Health and Social Care issued a National Patient Safety Alert and has advised clinicians to temporarily halt prescribing these medications to newly diagnosed patients. The supply chain remains fragile, with some medications becoming available intermittently. This unpredictability makes it difficult for patients to know if their prescriptions can be filled, leading them to contact multiple pharmacies. The shortages are not unique to the UK; the United States is also experiencing similar issues with ADHD medication supply. Healthcare providers have been advised to consider switching patients to alternative medications or different release formulations that may have better availability, though this requires careful clinical supervision. Due to the shortages, it may not be feasible to provide separate medication supplies for a child's school and home, requiring coordination between parents and schools to share a single supply.
